- Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
Key statistics
On Friday, Lexaria Bioscience Corp (LEXX:NAQ) closed at 2.35, 262.21% above the 52 week low of 0.6488 set on Jun 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.17 |
---|---|
High | 2.45 |
Low | 2.17 |
Bid | 2.32 |
Offer | 2.44 |
Previous close | 2.19 |
Average volume | 165.08k |
---|---|
Shares outstanding | 12.89m |
Free float | 11.78m |
P/E (TTM) | -- |
Market cap | 30.28m USD |
EPS (TTM) | -0.6851 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼